My Locations
Part of the Duke Cancer Institute
About Me
My practice and research focuses on patients who have female-specific cancers, such as ovarian, endometrial, cervical, vulvar or vaginal cancer. I offer my patients access to variety of treatments, ranging from surgery to chemotherapy and radiation. My dad was a physician, and my mom was a nurse, so I was exposed to health care at an early age. I enjoy my work on female cancers, because it is one of the few subspecialties to blend surgery and chemotherapy. It also gives me the chance to develop strong relationships with my patients, since I get to take care of my patients before and during their surgery, as well as continue to see them for the rest of their lifetime. I’ve found those patients, who have been able to face their diagnosis with unwavering optimism, to be incredibly inspiring. I have three children, so outside of work I spend as much time as I can with my family.
- Professor of Obstetrics and Gynecology, Obstetrics and Gynecology, Gynecologic Oncology 2013
- Member of the Duke Cancer Institute, Duke Cancer Institute 1994
Call for an Appointment
Areas of Expertise
Ratings and Reviews
The ratings and reviews are based on patient responses to the overall provider rating question from the survey. The question reads: “Using any number from 0 to 10, where 0 is the worst provider possible and 10 is the best provider possible, what number would you use to rate this provider?” Responses are converted to a 5-point rating system and applied consistently to all providers. Learn more about our survey process. Patients who see some types of providers receive a different version of the patient satisfaction survey. Those results are not available on DukeHealth.org.
Training and Education
In the News
Loading
Loading
Loading
Loading
Loading
Loading
Loading
Loading
Loading
Loading
Loading
Clinical Focus and Research
My research interests focus on clinical trials to identify novel therapies for female specific cancers. I also serve as director of gynecologic oncology clinical trials for our division and as associate director of clinical research for the Gynecologic Oncology Program at the Duke Cancer Institute. My ultimate goal is to translate our basic science findings into clinical trials and hopefully improve survival outcomes for women with gynecologic cancer.
-
NRG-CC008: Ovarian CancerIRB# PRO00111375 , NCT# NCT04251052
-
NRG-GY019 (Ovarian or Peritoneum Cancer)IRB# PRO00104152 , NCT# NCT04095364
-
NRG-GY026: Stage 1-IV Endometrial Serous Carcinoma or CarcinosarcomaIRB# PRO00112611 , NCT# NCT05256225
-
GOG-3078 Immunogen IMGN853-0421 (Ovarian and Fallopian Tube Cancers)IRB# PRO00112108 , NCT# NCT05445778
-
ComboMATCH-EAY191-N5 (HER2-Positive Cancers)IRB# PRO00115696 , NCT# NCT06126276
-
GOG-3083 XPORT-EC-042 SELINEXOR IN MAINTENANCE THERAPY FOR ADVANCED ENDOMETRIAL CANCERIRB# PRO00112976 , NCT# NCT05611931
-
GOG-3095 MK-2870-005 MK-2870 Monotherapy Vs. Physician's Choice in Endometrial CancerIRB# PRO00114641 , NCT# NCT06132958
-
Biobanking for OVCA (Ovarian Cancer)IRB# PRO00109365
-
Megestrol acetate compared with megestrol acetate and metformin to prevent endometrial cancerIRB# PRO00107762 , NCT# NCT04576104
-
Endometrial Cancer ConsortiumIRB# PRO00103465
-
AFT-50 EndoMAP Targeted Agents and/or Immunotherapy with Atezolizumab for Endometrial CancerIRB# PRO00107981 , NCT# NCT04486352
-
NRG-GY025 Endometrial CancerIRB# PRO00113684 , NCT# NCT05112601
-
GOG-3096 DS6000-109 (Ovarian, Primary Peritoneal, and Fallopian Tube Cancers)IRB# PRO00115756 , NCT# NCT06161025
-
EAY191-N4 ComboMATCH (Ovarian and Endometrial Cancers)IRB# PRO00114076 , NCT# NCT05554328
-
GOG-3101 MK-2870-020 for cervical cancerIRB# PRO00115757 , NCT# NCT06459180
-
GOG-3107 RAINFOL Rinatabart versus Investigator's Choice (Ovarian Cancer)IRB# PRO00116690 , NCT# NCT06619236
-
GY036 for stage 3/4 gynecologic cancers with pathogenic BRCA 1/2 mutation or HR deficiencyIRB# PRO00117512 , NCT# NCT06580314
- Gynecologic Oncology Group, Angeles Alvarez Secord, Paula S. Lee, Kathleen M. Darcy, Laura J. Havrilesky, Lisa A. Grace, Jeffrey R. Marks, and Andrew Berchuck. “Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study.” Gynecol Oncol 101, no. 3 (June 2006): 390–97. https://doi.org/10.1016/j.ygyno.2006.02.014.
- Secord, Angeles Alvarez, Victoria Bae-Jump, Floor Backes, Premal Thaker, Paola A. Gehrig, Rebecca A. Previs, Lindsay Borden, et al. “Genomic alterations, molecularly targeted therapy, and survival: a real-world Endometrial Cancer Molecularly Targeted Therapy Consortium cohort study.” Int J Gynecol Cancer 35, no. 5 (April 7, 2025): 101758. https://doi.org/10.1016/j.ijgc.2025.101758.
- Secord, Angeles Alvarez, Methodius G. Tuuli, Amy Geller, Alina N. Salganicoff, Sheila Burke, and Michelle P. Debbink. “A new vision for women's health research at the National Institutes of Health from the National Academies of Sciences, Engineering, and Medicine's Consensus Report: potential impact for gynecologic cancer care and research.” Int J Gynecol Cancer 35, no. 4 (April 2025): 101652. https://doi.org/10.1016/j.ijgc.2025.101652.
- Secord, A. A., and S. Siamakpour-Reihani. “Angiogenesis.” In Translational Advances in Gynecologic Cancers, 79–109, 2017. https://doi.org/10.1016/B978-0-12-803741-6.00005-7.
- Romano-Fitzgerald, S., A. B. De Meritens, A. A. Secord, and E. C. Kohn. “Invasion, metastasis, and angiogenesis.” In Principles and Practice of Gynecologic Oncology: Sixth Edition, 72–88, 2013.
- Frechtel-Gerzi, Roni, Daria Gerasimova, Einav Zeevi, Roni Monin, Hila Fishman, Inbar Schlachet-Drukerman, Helena Mumblat, et al. “Abstract B028: Preclinical effects of Tumor Treating Fields (TTFields) applied with cisplatin for treatment of cervical cancer.” In Cancer Research, 84:B028–B028. American Association for Cancer Research (AACR), 2024. https://doi.org/10.1158/1538-7445.dnarepair24-b028.
- Liu, J. F., M. Brady, U. A. Matulonis, A. Miller, E. C. Kohn, E. Swisher, W. Tew, et al. “LBA45 Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa).” In Annals of Oncology, 34:S1285–S1285. Elsevier BV, 2023. https://doi.org/10.1016/j.annonc.2023.10.039.
- John, Catherine, Xiaochang Shen, Boer Deng, Ziyi Zhao, Chunxiao Zhou, Victoria Bae-Jump, Angeles Alvarez Secord, Ines Batinic-Haberle, and Ivan Spasojevic. “Ascorbate exhibits anti-tumorigenic effects in pre-clinical models of endometrioid endometrial cancer (043).” In Gynecologic Oncology, 176:S37–38. Elsevier BV, 2023. https://doi.org/10.1016/j.ygyno.2023.06.516.
Insurance Accepted
Duke Health contracts with most major health insurance carriers and transplant networks, including the ones listed below.
-
Aetna
- Aetna Choice POS, Aetna Choice POS II
- Aetna Elect Choice HMO, Aetna Open Access Elect Choice
- Aetna Health Network Only, Aetna Health Network Option
- Aetna HMO
- Aetna Limited Benefit Insurance PPO
- Aetna Managed Choice POS
- Aetna Medicare Assure Plan (HMO D-SNP)
- Aetna Medicare Eagle Plan (PPO)
- Aetna Medicare Essential Plan (PPO)
- Aetna Medicare Value Plan (HMO)
- Aetna Open Access HMO, Open Access Aetna Select, Aetna Open Access Managed Choice
- Aetna Open Choice PPO
- Aetna PCP Coordinated POS Plan
- Aetna Quality Point of Service (QPOS)
- Aetna Select HMO
- Aetna Traditional Choice
- Aetna Voluntary Indemnity Group Plan
- Aetna Whole Health – Duke WakeMed WKCC
- Aetna/CVS Health
-
Ambetter
- Ambetter of North Carolina
-
Blue Cross Blue Shield of NC
- Blue Advantage
- Blue Medicare (HMO, PPO)*
- Blue Options (123, PPO, HSA)
- Blue Select
- NC State Employees Health Plan
-
*Duke HomeCare and Hospice does not participate in the plan.
-
Cigna
- Cigna Behavioral Health (*Limited eligibility)
- Cigna Choice Plus
- Cigna Connect Individual Family Plan
- Cigna Open Access
- Cigna Open Access Plus
-
*Please call Cigna Behavioral Heath to see if the provider is participating in your plan.
-
Duke Group Plans
- Duke Basic
- Duke Select
-
Experience Health
- Experience Health Medicare Advantage (HMO) Plan
- Gateway Health Alliance
- Healthgram
-
Humana
- Humana Choice (PPO)
- Humana Choice - Medicare Advantage (PPO)
- Humana ChoiceCare - Medicare Advantage (PPO)
- Humana Gold Choice - Medicare Advantage (PFFS)
- Humana Gold Plus - Medicare Advantage (HMO)
- Humana Medicare Advantage Group Plan - NC State Retirees
- MedCost
-
Medicare
- First Medicare Direct
- Medicare Part A
- Medicare Part B
-
NC Medicaid
- AmeriHealth Caritas North Carolina
- Carolina Complete Health
- Healthy Blue
- NC Medicaid Direct
- WellCare of North Carolina
-
TRICARE
- TRICARE Prime
- TRICARE Prime Remote
- TRICARE Select
-
United Healthcare
- AARP Medicare Advantage Plan 2 (HMO-POS)
- AARP Medicare Complete (HMO, PPO)*
- AARP Medicare Complete Essential (HMO)*
- All Savers Alternate Funding
- All Savers Fully Insured
- United Healthcare (HMO, PPO, POS)**
- United Healthcare Charter/Charter Balance/Charter Plus
- United Healthcare Choice/Choice Plus
- United Healthcare Core/Core Essential
- United Healthcare Navigate/Navigate Plus/Navigate Balanced
- United Healthcare Option PPO
- United Healthcare Passport Connect Choice/Choice Plus
- United Healthcare Passport Connect Options PPO
- United Healthcare Select/Select Plus
- United Healthcare Shared Services - Harvard Pilgrim/UHC Options PPO Network
- United Medical Resources (UMR)
-
*Duke HomeCare and Hospice and mental health providers do not participate with the plan.
-
**Duke Health does not participate in UHC plans on the Health Insurance Marketplace.
Before scheduling your appointment, we strongly recommend you contact your insurance company to verify that the Duke Health location or provider you plan to visit is included in your network. Your insurance company will also be able to inform you of any co-payments, co–insurances, or deductibles that will be your responsibility. If you proceed in scheduling an appointment and your health insurance benefits do not participate with Duke, your out of pocket liability may be higher. We will contact you regarding your coverage and patient liability. If you are uninsured, learn more about our financial assistance policy.
External Relationships
- AbbVie, Inc.
- GSK
- OncoQuest - Quest Pharma